Toward personalized therapeutic drug monitoring of ustekinumab in Crohn's disease: influence of previous exposure to biologics.

ABSTRACT:

Background

Unlike infliximab, ustekinumab (UST) has shown inconsistent associations between drug concentration and clinical efficacy across studies, with varying cutoff therapeutic trough levels (TLs) proposed.

Objectives

Given that patients have different histories of biologic use, we aimed to evaluate whether therapeutic TLs of ustekinumab require optimization in patients with Crohn's disease.

Design

Cohort study.

Methods

To assess whether ustekinumab has a potential therapeutic cutoff value, we evaluated and compared its 1-year TLs in 14 biologic-naïve patients and in 26 patients who were prescribed the drug after experiencing a loss of response to previous biologic therapies.

Results

The mean TL in the biologic-naïve patients was 3.41 µg/mL, which wa

SUBMITTER: Kwon Y 

PROVIDER: S-EPMC12619895 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature